Skip to main content
Erschienen in: Familial Cancer 4/2007

01.12.2007

Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer

verfasst von: Pavel Elsakov, Juozas Kurtinaitis, Valerij Ostapenko

Erschienen in: Familial Cancer | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

The aim of this prospective study is to assess the prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer. The study group comprised 19 women having multiple primary breast cancers (breast-breast, breast-other primary) who were either BRCA1 mutation carriers, or not. Appearance of a second primary cancer was recognised as the event and survival and second primary free cancer survival was calculated from the date of diagnosis to the secondary primary cancer. The results of this study show that the event free survival of women with familial breast cancer affected by a second primary cancer, who are BRCA1 mutation carriers is better, compared with women from the general population with breast cancer selected for second primary cancer sites and all second primary sites—P = 0.009 and P = 0.0078 respectively. In contrast, the event free survival of women with breast cancer affected by a second primary cancer, without a breast cancer family history, who are not BRCA1 mutation carriers is the same, as for women from the general population with breast cancer selected for second primary cancer sites and all second primary sites—P = 0.6417 and P = 0.4859 respectively. The median time from diagnosis of the first to second primary cancer in the mutation carrying, and non-carrying, groups was 8,7 and 1,9 years respectively. In the study group, the highest event free survival rates had been observed among those carrying the said mutations—66.7% at 5 years, and 33.3% at 10 years—in contrast with those not carrying the mutations, with rates of 30.8% and 15.4% respectively.
Literatur
1.
Zurück zum Zitat Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343:692–695PubMedCrossRef Ford D, Easton DF, Bishop DT et al (1994) Risks of cancer in BRCA1-mutation carriers. Lancet 343:692–695PubMedCrossRef
2.
Zurück zum Zitat Hemminki K, Vaittinen P, Easton D (2000) Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes. Int J Cancer 88:87–91 PubMedCrossRef Hemminki K, Vaittinen P, Easton D (2000) Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes. Int J Cancer 88:87–91 PubMedCrossRef
3.
Zurück zum Zitat Evans H, Lewis C, Robinson D et al (2001) Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility. Int J Cancer 94:758–759PubMedCrossRef Evans H, Lewis C, Robinson D et al (2001) Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility. Int J Cancer 94:758–759PubMedCrossRef
4.
Zurück zum Zitat Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP (1996) Better survival rates in patients with MLH1- associated hereditary colorectal cancer. Gastroenterology 110:682–687PubMedCrossRef Sankila R, Aaltonen LA, Jarvinen HJ, Mecklin JP (1996) Better survival rates in patients with MLH1- associated hereditary colorectal cancer. Gastroenterology 110:682–687PubMedCrossRef
5.
Zurück zum Zitat Percesepe A, Benatti P, Roncucci L, Sassatelli R, Fante R, Ganazzi D, Bellacosa A, Genuardi M, Neri G, Viel A, Ponz de Leon M (1997) Survival analysis in families affected be hereditary nonpolyposis colorectal cancer. Int J Cancer 71:373–376PubMedCrossRef Percesepe A, Benatti P, Roncucci L, Sassatelli R, Fante R, Ganazzi D, Bellacosa A, Genuardi M, Neri G, Viel A, Ponz de Leon M (1997) Survival analysis in families affected be hereditary nonpolyposis colorectal cancer. Int J Cancer 71:373–376PubMedCrossRef
6.
Zurück zum Zitat Lin KM, Shashidharan M, Ternent CA, Thorson AG, Blatchford GJ, Christensen MA, Lanspa SJ, Lemon SJ, Watson P, Lynch HT (1998) Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonopolyposis colorectal cancer kindreds and the general population. Dis Col Rec 41:428–433CrossRef Lin KM, Shashidharan M, Ternent CA, Thorson AG, Blatchford GJ, Christensen MA, Lanspa SJ, Lemon SJ, Watson P, Lynch HT (1998) Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonopolyposis colorectal cancer kindreds and the general population. Dis Col Rec 41:428–433CrossRef
7.
Zurück zum Zitat Porter DE, Cohen BB, Wallace MR et al (1994) Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome17q12–21. Br J Surg 81:1512–1515PubMedCrossRef Porter DE, Cohen BB, Wallace MR et al (1994) Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome17q12–21. Br J Surg 81:1512–1515PubMedCrossRef
8.
Zurück zum Zitat Gaffney DK, Brohet RM, Lewis CM et al (1998) Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutation. Radiother Oncol 47:129–136PubMedCrossRef Gaffney DK, Brohet RM, Lewis CM et al (1998) Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutation. Radiother Oncol 47:129–136PubMedCrossRef
9.
Zurück zum Zitat Lee JS, Wacholder S, Struewing JP et al (1999) Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA 2 mutation carriers. J Natl Cancer Inst 91:259–263PubMedCrossRef Lee JS, Wacholder S, Struewing JP et al (1999) Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA 2 mutation carriers. J Natl Cancer Inst 91:259–263PubMedCrossRef
10.
Zurück zum Zitat Foulkes WD, Wong N, Brunet JS, Begin LR, Zhang JC et al (1997) Germ-line BRCA1 mutation is an adverse prognosis factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 3:2465–2469PubMed Foulkes WD, Wong N, Brunet JS, Begin LR, Zhang JC et al (1997) Germ-line BRCA1 mutation is an adverse prognosis factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 3:2465–2469PubMed
11.
Zurück zum Zitat Robson M, Levin D, Federici M, Satagopan J, Bogolminy F et al (1999) Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91:2112–2117PubMedCrossRef Robson M, Levin D, Federici M, Satagopan J, Bogolminy F et al (1999) Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst 91:2112–2117PubMedCrossRef
12.
Zurück zum Zitat Haffty BG, Harrold E, Khan AJ, Pathare P, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M (2002) Outcome of conservatively managed early –onset breast cancer by BRCA1/2 STATUS. Lancet, 359:1471–1477PubMedCrossRef Haffty BG, Harrold E, Khan AJ, Pathare P, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M (2002) Outcome of conservatively managed early –onset breast cancer by BRCA1/2 STATUS. Lancet, 359:1471–1477PubMedCrossRef
13.
Zurück zum Zitat Chappuis P O, Rosenblatt J, Foulkes WD (1999) The influence of familial and hereditary factors on the prognosis of breast cancer. Ann Oncol 10:1163–1170PubMedCrossRef Chappuis P O, Rosenblatt J, Foulkes WD (1999) The influence of familial and hereditary factors on the prognosis of breast cancer. Ann Oncol 10:1163–1170PubMedCrossRef
14.
Zurück zum Zitat Gronwald J, Elsakov P, Gorski B, Lubinski J (2005) High incidence of 4153delA BRCA1 gene mutation in Lithuanian breast- and breast-ovarian cancer families. Breast Cancer Res Treat 94:111–113PubMedCrossRef Gronwald J, Elsakov P, Gorski B, Lubinski J (2005) High incidence of 4153delA BRCA1 gene mutation in Lithuanian breast- and breast-ovarian cancer families. Breast Cancer Res Treat 94:111–113PubMedCrossRef
15.
Zurück zum Zitat Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer (2000) Nov; 83(10):1301–1308 Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer (2000) Nov; 83(10):1301–1308
16.
Zurück zum Zitat Shih HA, Nathanson KL, Seal S, Collins N, Stratton MR, Rebbeck TR, Weber BL (2000) BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res 6(11):4259–4264PubMed Shih HA, Nathanson KL, Seal S, Collins N, Stratton MR, Rebbeck TR, Weber BL (2000) BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res 6(11):4259–4264PubMed
17.
Zurück zum Zitat Tikhomirova L, Sinicka O, Smite D, Eglitis J, Hodgson SV, Stengrevics A (2005) High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia. Fam Cancer. 4(2):77–84PubMedCrossRef Tikhomirova L, Sinicka O, Smite D, Eglitis J, Hodgson SV, Stengrevics A (2005) High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia. Fam Cancer. 4(2):77–84PubMedCrossRef
18.
Zurück zum Zitat Gorski B, Jakubovska A, Huzarski T, Byrski T et al (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families Int. J. Cancer 110:683–686CrossRef Gorski B, Jakubovska A, Huzarski T, Byrski T et al (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families Int. J. Cancer 110:683–686CrossRef
19.
Zurück zum Zitat Oszurek O, Gorski B, Gronvald J, Prosolow Z et al (2000) Founder mutation in the BRCA1 gene in west Belarussia breast-ovarian cancer families. Clin Genet 60:470–471CrossRef Oszurek O, Gorski B, Gronvald J, Prosolow Z et al (2000) Founder mutation in the BRCA1 gene in west Belarussia breast-ovarian cancer families. Clin Genet 60:470–471CrossRef
Metadaten
Titel
Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer
verfasst von
Pavel Elsakov
Juozas Kurtinaitis
Valerij Ostapenko
Publikationsdatum
01.12.2007
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2007
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-007-9139-7

Weitere Artikel der Ausgabe 4/2007

Familial Cancer 4/2007 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.